What is Lupron Depot?
Lupron Depot is an injectable form of leuprolide acetate, a synthetic hormone that acts as a gonadotropin-releasing hormone (GnRH) agonist. It suppresses production of sex hormones like testosterone in men and estrogen in women by overstimulating the pituitary gland, leading to a temporary shutdown of hormone release.[1]
How is Lupron Depot used?
Doctors prescribe it primarily for:
- Palliative treatment of advanced prostate cancer in men, to reduce testosterone levels and slow tumor growth.
- Management of endometriosis, uterine fibroids, and central precocious puberty in children.
- Other uses include breast cancer in premenopausal women and infertility treatments as part of assisted reproduction.[1][2]
It's administered as a depot (slow-release) intramuscular injection every 1, 3, 4, or 6 months, depending on the formulation (e.g., 7.5 mg, 11.25 mg, 22.5 mg, 30 mg, or 45 mg doses).[1]
Who makes Lupron Depot?
AbbVie (formerly part of Abbott Laboratories) manufactures and markets Lupron Depot in the US. It's available as a branded product with no generic version approved yet.[1][3]
When does Lupron Depot's patent expire?
Key patents covering Lupron Depot formulations and delivery systems, such as extended-release microspheres, extend protection into the late 2020s and early 2030s. For example:
- US Patent 8,815,317 (microsphere formulation) expires in 2032.
- US Patent 9,492,562 (injectable suspension) expires in 2033.
No biosimilars are approved, but challenges from competitors like Tolmar Therapeutics are ongoing.[4]
Check DrugPatentWatch.com for the latest patent status, litigation, and Paragraph IV challenges.
What are common side effects?
Patients often report hot flashes, injection-site reactions, fatigue, and decreased libido due to hormone suppression. Long-term risks include bone density loss, cardiovascular issues, and mood changes. In children, it may cause growth issues if not monitored.[1][2]
How does it compare to alternatives?
| Drug | Key Difference | Common Use |
|------|----------------|------------|
| Zoladex (goserelin) | Similar GnRH agonist; subcutaneous implant every 28 days or 12 weeks. | Prostate cancer, breast cancer. |
| Firmagon (degarelix) | GnRH antagonist; faster testosterone drop, no initial flare. Monthly injection. | Prostate cancer only. |
| Eligard (leuprolide alternative form) | Same active ingredient; subcutaneous vs. intramuscular. | Prostate cancer. |
Lupron Depot's depot system provides steady release but can cause an initial testosterone surge ("flare"), managed with anti-androgens.[1][2]
Sources:
[1] https://www.lupron.com/
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019135s115lbl.pdf
[3] https://www.abbvie.com/our-science/products.html
[4] https://www.drugpatentwatch.com/p/tradename/LUPRON%20DEPOT